Corcept Therapeutics insider plans small 5K-share sale under Rule 144

Rhea-AI Filing Summary

Corcept Therapeutics Inc. (CORT) – Form 144 filing discloses a proposed sale of 5,000 common shares by shareholder Joseph D. Lyon. The shares will be routed through Stifel Nicolaus & Co. on the NASDAQ with an estimated aggregate market value of $335,850 106.04 million shares outstanding, so the planned sale represents roughly 0.005 % of total shares.

The filer reports additional sales over the past three months totaling 18,527 shares for gross proceeds of $1.37 million. When combined with the proposed sale, Lyon’s total disposition for the rolling three-month window would reach 23,527 shares (~0.022 % of shares outstanding).

No purchase price was deferred; the 5,000 shares were acquired via stock-option exercise on 08/01/2025 and will be sold for cash. The filing contains the standard representation that the seller is unaware of undisclosed material adverse information and does not reference a Rule 10b5-1 plan.

Given the small size relative to the public float and absence of additional corporate disclosures, the filing appears routine and is unlikely to have a material impact on CORT’s valuation or trading dynamics.

Insights

Securities Analyst

TL;DR: Small routine insider sale (~0.005 % float) – immaterial to equity thesis.

At 5,000 shares, the proposed disposition equals just 0.005 % of outstanding stock. Even when aggregated with prior three-month sales, total volume is 23,527 shares or 0.022 %. Such levels are far below thresholds that typically trigger liquidity or sentiment concerns. There is no evidence of accelerated selling cadence, no 10b5-1 plan citation, and the options exercise suggests normal diversification. I view the filing as non-eventful for valuation or liquidity.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 procedural norms; governance risk negligible.

The notice supplies required broker, acquisition, and past-sale data, demonstrating compliance with Rule 144 aggregation rules. The representation that no undisclosed adverse information exists reduces informational-asymmetry concerns. The absence of large volume or concentrated timing mitigates governance red flags usually associated with opportunistic insider activity. Overall impact on shareholder interests is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St Louis MO 63102	5000	335850.00	106040000	08/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2025	Stock Option Exercise	Corcept Therapeutics Inc.			5000	08/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/01/2025	100	7350.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	05/01/2025	9350	672781.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	5000	390218.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	3877	284864.00
Joseph D. Lyon 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	200	14680.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Corcept Therapeutics (CORT) shares are being sold under this Form 144?

The filer plans to sell 5,000 common shares.

What is the estimated market value of the shares to be sold?

The aggregate market value disclosed is $335,850.

How significant is the sale relative to Corcept’s total shares outstanding?

5,000 shares equal roughly 0.005 % of the 106.04 million shares outstanding.

Has the same shareholder sold CORT shares recently?

Yes, 18,527 shares were sold in the past three months, bringing total recent dispositions to 23,527 shares.

What was the method of acquiring the shares now being sold?

The 5,000 shares were obtained via a stock-option exercise on 08/01/2025.

Which broker will execute the transaction?

Stifel Nicolaus & Co. Inc. is listed as the broker for the sale.